CMMB — Chemomab Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534248 ·
Israel
Last close
$2.03
Market Cap
$14.62M
52W High
$2.24
52W Low
$1.45
ADV30
42,968
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,850,000 | -1,773,000 | 11,808,000 | 5,906,000 | 1,113,000 |
| Dec 2025 | 0 | — | -1,974,000 | -1,873,000 | 13,812,000 | 7,564,000 | 1,478,000 |
| Sep 2025 | 0 | — | -1,844,000 | -1,742,000 | 12,368,000 | 6,974,000 | 1,137,000 |
| Jun 2025 | 0 | — | -2,262,000 | -2,057,000 | 11,129,000 | 5,448,000 | 1,430,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-111,618,000
Inventory
—
Receivables
$195,000
ST Investments
$2,802,000
EBIT TTM
$-9,567,000
Pretax Income TTM
$-8,995,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,567,000 | -8,995,000 | 13,812,000 | 1,478,000 | — | -11,130,000 |
| Dec 2024 | 0 | -14,739,000 | -13,945,000 | 16,964,000 | 3,427,000 | — | -15,386,000 |
| Dec 2023 | 0 | -25,459,000 | -24,221,000 | 22,151,000 | 5,154,000 | — | -23,611,000 |
| Dec 2022 | 0 | -28,533,000 | -27,646,000 | 43,063,000 | 6,840,000 | — | -20,370,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GTBP | GT Biopharma, Inc. | $14.14M | $0.39 | — |
| MTVA | MetaVia Inc. | $15.34M | $2.97 | — |
| CYCN | Cyclerion Therapeutics, Inc. | $13.86M | $3.20 | — |
| BLRX | BioLineRx Ltd. | $13.75M | $3.16 | — |
| COCP | Cocrystal Pharma, Inc. | $15.58M | $1.13 | — |
News headlines (Yahoo Finance, 1h cache)
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 12:00 · Yahoo
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2026-03-19 12:00 · Yahoo
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-17 13:00 · Yahoo
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
2025-12-02 13:00 · Yahoo
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
2025-11-24 13:00 · Yahoo
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-20 13:00 · Yahoo
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
2025-11-06 13:00 · Yahoo
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
2025-10-23 14:27 · Yahoo
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
2025-10-22 14:18 · Yahoo
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
2025-10-17 15:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.